MIGUEL JOSÉ
MARTÍN JIMÉNEZ
Catedrático de universidad
University of North Carolina at Chapel Hill
Chapel Hill, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von University of North Carolina at Chapel Hill (16)
2022
-
Effects of capecitabine as part of neo-/adjuvant chemotherapy – A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients
European Journal of Cancer, Vol. 166, pp. 185-201
2019
-
A Pathology-Based Combined Model to Identify PAM50 Non-luminal Intrinsic Disease in Hormone Receptor-Positive HER2-Negative Breast Cancer
Frontiers in Oncology, Vol. 9, Núm. APR
-
B Cells and T Follicular Helper Cells Mediate Response to Checkpoint Inhibitors in High Mutation Burden Mouse Models of Breast Cancer
Cell, Vol. 179, Núm. 5, pp. 1191-1206.e21
-
Evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for hormone receptor–positive metastatic breast cancer: a pooled analysis from the LEA (GEICAM/2006-11_GBG51) and CALGB 40503 (Alliance) trials
European Journal of Cancer, Vol. 117, pp. 91-98
2017
-
A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse
Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044
2016
-
Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study
Breast Cancer Research and Treatment, Vol. 156, Núm. 1, pp. 81-89
2015
-
Defining breast cancer intrinsic subtypes by quantitative receptor expression
Oncologist, Vol. 20, Núm. 5, pp. 474-482
2014
-
Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: Investigation in the QUASAR2 study, systematic review, and meta-analysis
Journal of Clinical Oncology, Vol. 32, Núm. 10, pp. 1031-1039
-
Predicting response and survival in chemotherapy-treated triple-negative breast cancer
British Journal of Cancer, Vol. 111, Núm. 8, pp. 1532-1541
2013
-
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer
Breast Cancer Research and Treatment, Vol. 138, Núm. 2, pp. 457-466
-
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal a breast cancer
Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 203-209
-
Reply to Y. Yamamoto et al
Journal of Clinical Oncology
2012
-
PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers
BMC Medical Genomics, Vol. 5
2011
-
Assessment of topoisomerase II α status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in Situ hybridization
American Journal of Pathology, Vol. 178, Núm. 4, pp. 1453-1460
2009
-
Reply to L.C. Panasci
Journal of Clinical Oncology
-
Reply to R.S. Mehta et al
Journal of Clinical Oncology